Side-by-side · Research reference
SemaglutidevsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship15/53 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Semaglutide
Survodutide
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
—
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
—
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
Survodutide
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
Once weekly
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
—
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
—
Timing
Any time of day, with or without food
—
03Metabolic / Fat Loss Evidence
Parameter
Semaglutide
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Semaglutide
Survodutide
GI symptoms
Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Injection site reaction
Mild erythema, pruritus
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
—
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
—
Gallbladder events
Increased cholelithiasis
—
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Semaglutide
Survodutide
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
Survodutide
— no documented stacks